Biotechnology

ProImmune Launches B Cell ELISpot Assay Service

Published in Vaccine Weekly, May 2nd, 2012

2012 MAY 2 -- ProImmune Ltd., a leader in services for understanding immune responses, has launched the B cell ELISpot assay as a service. The B cell ELISpot assay is central to the characterization of adaptive immune responses to infection, immune modulators, vaccines and therapeutic agents.

Used to quantify the number of memory B cells that can be re-stimulated to produce antibody against a specific antigen, B cell ELISpot enables the activity of antibody-secreting memory B cells to be characterized at a cellular level. This gives a more detailed reading of immune responses in contrast to an ELISA-type assay, which measures total levels of secreted...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2012-05-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry